Mahad ramp targets 75%–80% utilization for EBITDA positivity

Oriental Aromatics Limited — Q1 FY27 Earnings Call (Quarter ended 30 June 2026)

1. Overall Tone of Management: Optimistic

• Management called Q1 “a positive start” and “encouraging,” citing “healthy year-on-year growth,” “sequential recovery in profitability,” and “direction of our performance is encouraging.”
• They also provided a near-term growth trajectory (“10% to 15% growth in our sales in the next one year”) and reiterated a utilization ramp plan for Mahad.

2. Key Themes from Management Commentary

• Top-line growth driven by volumes: Revenue up ~15% YoY to ~₹260 cr, with sales volume up 22% YoY and production volume up 18% YoY.
• Sequential margin improvement despite cost headwinds: EBITDA margin improved 71 bps sequentially to 7.62%, but remains pressured by higher raw material costs.
• Business resilience via diversification: Continued emphasis on resilience across Flavors/Fragrances, Specialty Aroma Ingredients, and Camphor & Terpene Chemicals.
• Specialty Aroma Ingredients: structural competitiveness + disciplined response
• Market described as “highly competitive” with capacity additions in Asia pressuring selling prices.
• Management highlighted structural cost actions: process re-engineering, yield improvement, energy optimization, internalization of intermediaries, multi-chemistry utilization.
• Camphor: overcapacity remains structural
• Q1 volumes supported by seasonality (inventory build ahead of festive period), but domestic market faces “structural overcapacity”.
• Focus on competitive advantages (quality/regulatory, pharma-grade camphor, B2B relationships, Saraswati & 3 Pine brands).
• Mahad facility: commercialization progressing but still a profitability drag
• Customer feedback “encouraging,” commercial shipments progressing, participating in RFQs.
• However, management explicitly states Mahad is not yet at utilization levels to absorb fixed costs; target 75%–80% utilization to become EBITDA positive.
• Financial discipline / capital allocation
• Net debt-to-equity improved to 0.56x (from 0.58x in March 2026).
• Priority: maximize utilization of existing assets before major expansion.
• Macro/operating environment remains mixed
• Ongoing risks: raw material inflation, FX movement, geopolitical developments, competitive pricing.
• They stress vigilance and partial pass-through capability.

3. Q&A Analysis

Theme A: Utilization, capacity ramp, and revenue upside (Mahad + overall plants)

• Core questions
• Current utilization for overall business and Mahad; peak utilization and what revenue could be at full utilization.
• CAPEX cycle completion and remaining growth runway over next 5 years.
• Management response
• Mahad utilization: 50%–60% currently.
• Other plants (ex hydrogenation): 85%–90%; fragrance compounding has “substantial additional ability.”
• Near-term sales goal: “10% to 15% growth in our sales in the next one year.”
• Mahad ramp: “next few quarters” for better utilization; long-term framing emphasized (Fragrance division value capture from backward integration).
• Notable / evasive elements
• When asked for a specific “full utilization” revenue number, management deferred to “long-term strategic goal” and did not provide a hard figure.
• For the 5-year growth runway, they redirected to the “Oriental story” (backward integration benefits) rather than giving a clear segment mix or numeric roadmap.

Theme B: Margins outlook vs raw material volatility / pass-through

• Core questions
• How margins will look given product mix and raw material price pressure.
• Whether raw material price increases are being passed through in Q2; margin impact.
• Management response
• Margin visibility described as limited: “crystal ball” due to geopolitics; “very watchful.”
• Identified specific cost pressure: Alpha-Pinene expected to remain expensive; petro inputs “seesaw.”
• Pass-through: “Wherever it’s been possible… we have been very, very successful,” but capacity additions in Asia make pass-through harder in Specialty Aroma Ingredients and Camphor.
• Mitigation: “step-up pass-through process… to at least cover the foreign exchange impact as well as any raw material hike impact.”
• Notable / evasive elements
• No quantitative margin guidance for upcoming quarters; answers remained qualitative and scenario-based.

Theme C: Camphor import regulation / anti-dumping / government discussions

• Core questions
• Status of discussions on ban/import restrictions for camphor.
• Whether they will approach authorities / industry association for anti-dumping duties.
• Camphor market structure: retail vs B2B split; pricing drivers vs China.
• Management response
• Government discussion: no further development this quarter.
• Anti-dumping: in this call, management did not indicate active pursuit; earlier stance in prior calls was “watching the situation.”
• Contribution split: refused detailed retail/B2B breakdown; reiterated ~one-third each across the three verticals.
• Pricing: confirmed double-digit increase in Indian camphor powder; attributed to Alpha-Pinene cost up ~70%–80% over five months; “they continue to stay firm.”
• Notable / evasive elements
• Repeated refusal to provide granular breakdowns (retail vs B2B; China import pricing specifics).

Theme D: Mahad commercialization mechanics, inventory, and margin improvement timeline

• Core questions
• Whether Mahad production is being inventorized; inventory buildup explanation.
• Scope for margin improvement given margins have “stuck” around ~7% and Mahad drag.
• When Mahad becomes EBITDA neutral and what utilization threshold is required.
• Management response
• Inventory: acknowledged “inventory buildup” due to challenged access to one raw material (petrol-driven); confident it will be sold “in the near future.”
• Margin improvement: framed as market-cycle dependent for generics but confident they’ll capitalize when opportunities arise; emphasized basket-level EBITDA.
• Timeline: reiterated long commercialization cycle; “500 days to 1,000 days” to see the light of the day; “as and when it happens, we will be informing.”
• Notable / evasive elements
• Avoided a firm “Q3/Q4 EBITDA neutral” date; used long-cycle language and “we will inform” phrasing.

Theme E: Other operational metrics: export contribution, R&D, tax

• Core questions
• Export contribution for FY27; R&D spend %; effective tax rate.
• Management response
• Export contribution: 35% in the quarter; expected to remain in same range.
• R&D: around 2%–2.5% of sales.
• Tax: ~25% effective rate.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Sales growth (near-term): “10% to 15% growth in our sales in the next one year.”
• Mahad utilization target: “75% to 80% utilization” to reach EBITDA positive.
• Tax rate: “around 25%” for FY27 (and implied FY28 similarly in Q&A).
• Export contribution: “35% this quarter” and “stay in the same range.”

Implicit signals (qualitative)

• Sequential momentum: Q1 described as “positive start” with sequential profitability recovery; management expects to “convert this operational momentum into sustained improvements.”
• Margin uncertainty remains high: repeated “fluid” / “crystal ball” language suggests no strong confidence in near-term margin expansion.
• Mahad ramp is progressing but not yet fixed-cost absorbing: commercialization progressing, but still “impact consolidated profitability.”

5. Standout Statements (direct / high-signal)

• Near-term growth target: “trajectory of anywhere between 10% to 15% growth in our sales in the next one year.”
• Mahad utilization + profitability threshold: “move the facility towards 75% to 80% utilization, where we believe Mahad will become EBITDA positive.”
• Margin visibility constrained by geopolitics: “looking at the crystal ball” / “global geopolitical situation is having an impact.”
• Raw material cost driver called out clearly: “Alpha-Pinene prices… gone up by almost 70% or 80%… they continue to stay at this high price point.”
• Inventory explanation (Mahad): “there is an inventory buildup… initiated because of… challenged access to one raw material… we are very, very confident that we will be able to sell it in the near future.”
• Strategic reframing of CAPEX value capture: “the logic of the CAPEX… has not been to only benefit the company by selling the ingredients… These products… have been extensively used by our Fragrance division.”

6. Red Flags / Positive Signals

Red flags
– No quantitative margin guidance despite margin being a key investor concern; management repeatedly uses uncertainty language (“crystal ball,” “fluid”).
– Mahad remains a consolidated profitability drag and timeline is still framed with long-cycle uncertainty (“500–1,000 days,” “as and when it happens”).
– Inventory buildup acknowledged (even if expected to be sold soon), which can mask near-term profitability and working capital volatility.
– Pass-through limitations explicitly tied to Asia capacity additions; suggests margin risk could persist.

Positive signals
– Sequential EBITDA margin improvement (71 bps) while volumes grew strongly.
– Operational execution credibility on utilization: most plants already at 85%–90% (ex Mahad), implying limited operational slack outside Mahad.
– Disciplined capital allocation: net debt-to-equity improving to 0.56x.
– Pass-through success where possible and mitigation via step-up processes for FX/raw material.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current (Q1 FY27): More Optimistic
• Q1 framed as “positive start,” “sequential recovery in profitability.”
• Prior calls:
• Q4/FY26 (May 2026): emphasized FY26 margin compression and “consolidation mode,” with headwinds expected to continue.
• Q3/FY26 (Feb 2026): margins were under pressure; Mahad described as near-term drag; “pricing remains under pressure.”
• Q2/H1 FY26 (Nov 2025): margins lower as “conscious choice” to protect volumes; Mahad drag expected to normalize.
• Shift explanation
• Management now highlights sequential margin improvement and stronger volume growth.
• However, they still avoid firm margin targets and keep Mahad ramp uncertainty alive—so optimism is incremental, not a full confidence reset.

b. Tracking Past Commitments vs Outcomes

1) Mahad EBITDA neutral at 75%–80% utilization
– Past statement (Q4/FY26, May 2026): “at 75%, 80% utilization, we should be in a position to… make it EBITDA neutral.”
– Current (Q1 FY27): reiterates same threshold; Mahad still at 50%–60% utilization.
– Assessment: ⏳ Delayed (still not at target utilization; EBITDA positive not yet achieved at consolidated level).

2) Mahad commercialization ramp / approvals progressing
– Past (Q4/FY26): sampling cycles progressing; commercial shipments commenced; RFQs for H2 2026.
– Current (Q1 FY27): “commercial shipments are progressing,” participating in RFQs; customer feedback encouraging.
– Assessment: ✅ Partially delivered (commercialization progress acknowledged), but profitability impact still not resolved.

3) Margin recovery to target range (8%–10%)
– Past (Q2/H1 FY26, Nov 2025): priority to “restore margins to our target range of 8% to 10%.”
– Current: EBITDA margin is 7.62% in Q1 FY27; management does not re-commit to 8–10% in the near term and calls margin outlook “crystal ball.”
– Assessment: ⏳ Delayed / not delivered (still below target range; confidence reduced).

c. Narrative Shifts

• From “pricing cycle turning” to “structural cost discipline + basket EBITDA”:
• Earlier calls leaned more on pricing normalization as a driver.
• Current call emphasizes process re-engineering and cost position independent of pricing cycle, plus “basket-level EBITDA.”
• Mahad narrative remains consistent but becomes more operationally specific:
• Current call adds clearer detail on inventory buildup due to raw material access and utilization levels (50%–60%).
• Camphor regulatory narrative remains static:
• Government discussion: “no further development” (current) vs “dialogue initiated” (earlier).

d. Consistency & Credibility Signals

• Medium credibility
• Consistent on: Mahad is the key drag; utilization must rise to reach EBITDA positive; raw material volatility is a major driver.
• Less consistent on: timing certainty for margin recovery—management repeatedly frames outcomes as dependent on external conditions and long cycles, with limited quantitative commitments.
• Credibility is supported by operational metrics (utilization ranges, export %, net debt-to-equity trend), but margin path remains under-specified.

e. Evolution of Key Themes

• Demand/volumes: Improving/stable direction (Q1 FY27 strong YoY volume growth; prior quarters also showed volume resilience).
• Margins: Deteriorated structurally in FY26; Q1 FY27 shows sequential improvement but still constrained.
• Mahad: Stable theme (ramp-up drag), but utilization now quantified (50–60%).
• Raw material inflation: Persistent and increasingly specific (Alpha-Pinene now explicitly quantified as 70–80% up).
• Camphor overcapacity: Persistent structural headwind; no evidence of resolution.

f. Additional Insights (Cross-Period Intelligence)

• A risk is becoming more explicit: management now ties margin uncertainty not only to raw materials but also to capacity additions in Asia limiting pass-through—suggesting the pricing headwind may last longer than “temporary.”
• Working capital/inventory risk is recurring: earlier calls discussed inventory as strategic; current call confirms inventory buildup tied to raw material access—this can delay margin recovery even if sales eventually occur.
• Defensiveness in Q&A increased around granularity: repeated refusals to provide retail/B2B splits and division-level details suggest management is managing expectations on segments that may not look strong.